Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.
Anirban Basu, PhD
Advertisement
Articles by Anirban Basu, PhD
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Advertisement
Latest Updated Articles
- One Size Does Not Always Fit All in Value Assessment
November 13th 2019
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5